Project
INCMOR0208-301
Ongoing - recruitment closed · 2021 until 2099
Fehr Martin, Bürki Ramona, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2021
End Date
2099
Financing
Industry
Labels
lymphoma
Brief description/objective
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINAL ZONE LYMPHOMA (MZL)